CIBG 166a

Drug Profile

CIBG 166a

Alternative Names: CIGB-166a

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Recombinant proteins
  • Mechanism of Action Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Wet age-related macular degeneration

Most Recent Events

  • 31 Dec 2015 CIBG 166a is available for licensing as of 31 Dec 2015.
  • 31 Dec 2015 Center for Genetic Engineering and Biotechnology has patent protection for CIGB 166a in Cuba
  • 31 Dec 2015 Early research in Cancer in Cuba (unspecified route), before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top